Epogen :: Science Biology Papers

Epogen Epogen is produced by the company Amgen. Amgen located atThousand Oaks, California, is a global biotechnology company. It discovers, develops, manufactures, and markets human therapeutics based on advanced cellular and molecular biology. Amgen, founded in 1980, is now the largest biotechnology company in the world. It has 4,200 employers around the world and 2,700 of the 4,200 workers, work at the headquarters in Thousand Oaks. Amgen has centers of research in "Boulder, Colorado and Toronto, Canada; clinical research centers in Cambridge, England and Melbourne, Australia; the international distribution center in Louisville, Kentucky, fill and finish facility in Junco, Puerto Rico; and European regional headquarters in Lucerne, Switzerland. Amgen has other international offices that are located in Austria, Australin, Belgium, Canada, China, France, Germany, Italy, Japan, the Netherlands, Hong Kong, Portugal, Spain, and the United Kingdom." (Amgen 1996) Amgen's first product, Epogen was approved in June 1989 for use in the United States. Neupogen (filgrastim) Amgen's second product, received approval for use in February 1991, is used for preventing infections in cancer patients that receive chemotherapy for bone marrow and peripheral blood progenitor cell transplantation patients and treatment for chronic neutropenia, which is a rare blood disorder. Amgen has research in the areas of hematopoiesis, neurobiology, inflammation/autoimmunity, and soft tissue repair and regeneration. Products from the research, in the four areas mentioned from above, may, sometime in the future, be used in treating conditions characterized by disorders of blood and bone marrow, neurodegenerative diseases such as ALS, Parkinson's, Alzheimer's, or traumatic nerve injury. Epogen Epoetin Alfa recombinant Epogen, or Epogen, has 3,000 units of recombinant Epoetin Alfa, 2.5 mg Albumin (Human) in sterile buffered solution (pH 6.9 +/- 0.3) of sodium citrate (5.8mg), sodium chloride (5.8mg), citric acid (0.06mg), in Water for injection. Its uses are stimulating the body to make red blood cells, treatments of anemia (loss or reduction of red blood cells) associated with chronic renal failure or anemia caused by AZT (zidovudine) in HIV-infected persons. Before Epogen was produced or used, blood transfusions and male hormone therapy was used in treating anemia, which was caused by chronic renal failure. Epogen Studies Studies on Epogen are available from Amgen, Food and Drug Administration (FDA), and the Journal of the American Society of Nephrology. One study by Amgen was "to establish the safety and efficacy of EPOGEN in pediatric patients" (Amgen 89), the second study from FDA, was about erythropoietin, which is